Development and application of IgY antibodies in anti-infective therapies

This approach is based on the optimization of IgY antibodies, a special class of immunoglobulins derived from the egg yolk of poultry. Birds, especially chickens, can produce large quantities of IgY antibodies, which leads to more cost- and volume-efficient procurement compared to the production of mammalian antibodies. The development of these antibodies aims to improve their efficacy by giving them highly specific binding properties that make them ideal for the precise targeting of specific molecules or pathogens associated with certain diseases. In addition, IgY antibodies derived from avian egg yolk offer an alternative and ethically acceptable source compared to mammalian antibodies. This method avoids invasive and costly procedures associated with obtaining conventional antibodies. On the other hand, IgY antibodies generally show less cross-reactivity with mammalian proteins and are more stable under unfavorable conditions, such as pH fluctuations and extreme temperatures, which facilitates their storage and transportation without significant loss of biological activity.